Official establishment of Icomoon's first fund

On March 15, 2022, Icomoon capital’s first equity investment fund: Nanjing Jiansu Equity Investment Partnership (limited partnership) (AMAC code: SQW831) has completed its registration through Asset management association China, marking Icomoon capital has successfully completed the first fund raising and registration.

The investment target of Nanjing Jiansu Equity Investment Partnership (Limited partnership) is Beijing Digital Precision Medical Technology Co., LTD. ("DPM").On July 19, 2022, DPM announced the completion of a B round of financing worth hundreds of millions of yuan. This round of financing was jointly led by SoftBank China Capital and Zhongguancun Longmen Investment, followed by Hangzhou Risheng and Jiangsu Haoyue Fund, and Kaicheng Capital acted as financial advisor.This round of financing will further accelerate the company's product innovation, marketing and team building pace.

DPM Company was incubated in the Key Laboratory of Molecular Imaging, Chinese Academy of Sciences. After realizing the transformation of scientific and technological achievements through "intellectual property pricing and investment", DPM company has achieved rapid development.Relying on strong laboratory at the forefront of technology, the company independent research and development and production, fluorescence molecular imaging fluorescence endoscope system, and the white light endoscopy camera system, and research and development and planning of molecular imaging contrast agents, magnetic nanoparticles such as whole series of molecular imaging and imaging devices, for industry leaders in the field of molecular imaging technology.

With favorable policies and product iteration and upgrading, domestic high-end endoscope manufacturers ushered in a golden development period to break foreign monopoly.Digital precision has created three series of high-end optical molecular imaging surgical navigation equipment and white light endoscope camera system product matrix, and is also constantly improving 3D endoscope, 3D fluorescence endoscope and broad spectrum artificial intelligence endoscope product lines.At present, 13 products have obtained the NMPA product registration certificate, and obtained the European CE certification at the same time.

The products independently developed by DPM company have been proved to be effective and safe through rigorous evidence-based medicine superior clinical trials, and have received special approval from the National Drug and Drug Administration and Beijing Municipal Drug and Drug Administration for innovative medical devices.In 2021, the company took the lead in formulating technical standards in the industry and completed and released two group standards to the whole country.

DPM Company is the crystallization of national research and accumulation of many major projects.The previous research has been supported by the National 973 Program, the National Natural Science Foundation of China's Major Scientific Research Instrument Special Project, the National Ministry of Science and Technology Nano Special Project and other national key projects, and DPM has led the national Ministry of Science and Technology's key project of "digital diagnosis and treatment equipment Research and development", which has made a major breakthrough in the intraoperative accurate imaging of liver cancer.In the core technology, he has obtained the American invention patent, PCT invention patent, national invention patent, software copyright and other intellectual property rights more than 100.Relevant achievements won a national scientific and technological progress second prize, second prize of national technological invention, the 43rd Geneva international invention exhibition gold award, 23rd national invention exhibition gold award, China medical equipment innovation entrepreneurship competition first prize, national WeiJianWei 8 excellent domestic endoscope products enterprise and other honorary titles.

Precision medicine is an important way to improve the level of diagnosis and treatment and realize personalized medicine.Molecular imaging technology has been rated as one of the top ten frontiers of medical science with the most potential for development in the future. The rise of molecular imaging has brought new opportunities for the development of precision medicine.At present, DPM uses optical molecular imaging surgery navigation technology to layout precision surgery, and relies on molecular imaging contrast agent to create a closed loop of "equipment + consumables".In the future, DPM will further advance from the field of precision surgery into the field of precision health by relying on the new magnetic nanoparticles disease screening imaging technology.